{"classes":[{"categories":[{"measurements":[{"comment":"The MTD was not found because the study was halted due to manufacturer withdrawal of support for low enrollment.","groupId":"OG000","value":"NA"},{"comment":"The MTD was not found because the study was halted due to manufacturer withdrawal of support for low enrollment.","groupId":"OG001","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"The MTD is the dose level at which no more than 1 of up to 6 participants experience a dose-limiting toxicity (DLT) during the DLT evaluation window(s), or the dose below that at which at least 2 (of ≤6) participants have DLT. A dose-limiting toxicity (DLT) is defined as: any grade 3, 4, or 5 toxicity, if not incontrovertibly due to disease progression or an extraneous cause, and deemed possibly, probably or definitely related to interleukin-15 (IL-5) by the principal investigator (PI) or designee during the first 28 days of treatment. Grade 3 is severe. Grade 4 is life threatening. Grade 5 is death related to adverse event.","groups":[{"description":"Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day on days 1-5 of each of six cycles.","id":"OG000","title":"Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab"},{"description":"Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a second dose level of 2 mcg/kg/day on days 1-5 of each of six cycles.","id":"OG001","title":"Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"First 28 days of treatment","title":"Maximum Tolerated Dose (MTD) of Interleukin 15","type":"PRIMARY","unitOfMeasure":"mcg/kg"}